Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

[IgG4-Related Orbitopathy as an Important Differential Diagnosis of Advanced Silent Sinus Syndrome. German version].

Jurkov M, Olze H, Klauschen F, Bertelmann E, Schneider U, Arens P.

HNO. 2020 Feb 14. doi: 10.1007/s00106-019-00798-9. [Epub ahead of print] Review. German.

PMID:
32060570
2.

Support of a molecular tumour board by an evidence-based decision management system for precision oncology.

Lamping M, Benary M, Leyvraz S, Messerschmidt C, Blanc E, Kessler T, Schütte M, Lenze D, Jöhrens K, Burock S, Klinghammer K, Ochsenreither S, Sers C, Schäfer R, Tinhofer I, Beule D, Klauschen F, Yaspo ML, Keilholz U, Rieke DT.

Eur J Cancer. 2020 Mar;127:41-51. doi: 10.1016/j.ejca.2019.12.017. Epub 2020 Jan 23.

PMID:
31982633
3.

IgG4-related orbitopathy as an important differential diagnosis of advanced silent sinus syndrome.

Jurkov M, Olze H, Klauschen F, Bertelmann E, Schneider U, Arens P.

HNO. 2020 Jan;68(Suppl 1):65-68. doi: 10.1007/s00106-019-00799-8.

PMID:
31915884
4.

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.

Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S.

Breast Cancer Res. 2019 Dec 11;21(1):142. doi: 10.1186/s13058-019-1231-z.

5.

Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.

Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, Rückert JC, Neudecker J, Schweizer L, Klauschen F, Horst D, Hummel M, Dietel M, von Laffert M.

Lung Cancer. 2019 Dec;138:43-51. doi: 10.1016/j.lungcan.2019.10.005. Epub 2019 Oct 11.

PMID:
31634654
6.

Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature.

Liebs S, Nonnenmacher A, Klauschen F, Keilholz U, Vecchione L.

ESMO Open. 2019 Aug 16;4(4):e000528. doi: 10.1136/esmoopen-2019-000528. eCollection 2019. Review.

7.

Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases.

Jurmeister P, Bockmayr M, Seegerer P, Bockmayr T, Treue D, Montavon G, Vollbrecht C, Arnold A, Teichmann D, Bressem K, Schüller U, von Laffert M, Müller KR, Capper D, Klauschen F.

Sci Transl Med. 2019 Sep 11;11(509). pii: eaaw8513. doi: 10.1126/scitranslmed.aaw8513.

PMID:
31511427
8.

Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.

Jurmeister P, Bockmayr M, Treese C, Stein U, Lenze D, Jöhrens K, Friedling F, Dietel M, Klauschen F, Marsch W, Fiedler E, von Laffert M.

J Dtsch Dermatol Ges. 2019 Aug;17(8):800-808. doi: 10.1111/ddg.13917.

PMID:
31437373
9.

Immunhistochemische Analyse von Bcl-2, nukleärem S100A4, MITF und Ki67 zur Risikostratifizierung von Melanomen im Frühstadium - ein kombinierter immunhistochemischer Score.

Jurmeister P, Bockmayr M, Treese C, Stein U, Lenze D, Jöhrens K, Friedling F, Dietel M, Klauschen F, Marsch W, Fiedler E, von Laffert M.

J Dtsch Dermatol Ges. 2019 Aug;17(8):800-809. doi: 10.1111/ddg.13917_g. German.

PMID:
31437365
10.

Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.

Bockmayr M, Klauschen F, Maire CL, Rutkowski S, Westphal M, Lamszus K, Schüller U, Mohme M.

Cancer Immunol Res. 2019 Sep;7(9):1401-1411. doi: 10.1158/2326-6066.CIR-18-0939. Epub 2019 Jul 2.

PMID:
31266783
11.

Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non-Small-Cell Lung Cancer.

Martin J, Lehmann A, Klauschen F, Hummel M, Lenze D, Grohé C, Tessmer A, Gottschalk J, Schmidt B, Pau HW, Witt C, Moegling S, Kromminga R, Jöhrens K.

Clin Lung Cancer. 2019 Sep;20(5):350-362.e4. doi: 10.1016/j.cllc.2019.04.012. Epub 2019 May 11.

PMID:
31175009
12.

Histomorphological and molecular profiling: friends not foes! Morpho-molecular analysis reveals agreement between histological and molecular profiling.

Hoberger M, von Laffert M, Heim D, Klauschen F.

Histopathology. 2019 Nov;75(5):694-703. doi: 10.1111/his.13930. Epub 2019 Sep 5.

PMID:
31152602
13.

Regulatory T cells differ from conventional CD4+ T cells in their recirculatory behavior and lymph node transit times.

Tong AA, Forestell B, Murphy DV, Nair A, Allen F, Myers J, Klauschen F, Shen C, Gopal AA, Huang AY, Mandl JN.

Immunol Cell Biol. 2019 Oct;97(9):787-798. doi: 10.1111/imcb.12276. Epub 2019 Jun 17.

PMID:
31127976
14.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G.

Breast Cancer Res Treat. 2019 Aug;176(3):557-568. doi: 10.1007/s10549-018-05112-9. Epub 2019 May 7.

PMID:
31065870
15.

[Detection and interpretation of somatic variants in molecular pathology].

Merkelbach-Bruse S, Rehker J, Siemanowski J, Klauschen F.

Pathologe. 2019 May;40(3):243-249. doi: 10.1007/s00292-019-0603-6. German.

PMID:
31037375
16.

Variant classification in precision oncology.

Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A.

Int J Cancer. 2019 Dec 1;145(11):2996-3010. doi: 10.1002/ijc.32358. Epub 2019 May 21.

PMID:
31008532
17.

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.

Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C.

Clin Cancer Res. 2019 Jul 1;25(13):3986-3995. doi: 10.1158/1078-0432.CCR-18-3258. Epub 2019 Apr 12.

PMID:
30979740
18.

Somatic genome alterations in relation to age in lung adenocarcinoma.

Meucci S, Keilholz U, Heim D, Klauschen F, Cacciatore S.

Int J Cancer. 2019 Oct 15;145(8):2091-2099. doi: 10.1002/ijc.32265. Epub 2019 Mar 28.

PMID:
30859574
19.

Tissue clonality of dendritic cell subsets and emergency DCpoiesis revealed by multicolor fate mapping of DC progenitors.

Cabeza-Cabrerizo M, van Blijswijk J, Wienert S, Heim D, Jenkins RP, Chakravarty P, Rogers N, Frederico B, Acton S, Beerling E, van Rheenen J, Clevers H, Schraml BU, Bajénoff M, Gerner M, Germain RN, Sahai E, Klauschen F, Reis E Sousa C.

Sci Immunol. 2019 Mar 1;4(33). pii: eaaw1941. doi: 10.1126/sciimmunol.aaw1941.

20.

Systems proteogenomics for precision oncology.

Klauschen F.

Oncotarget. 2019 Jan 22;10(7):692-693. doi: 10.18632/oncotarget.26601. eCollection 2019 Jan 22. No abstract available.

Supplemental Content

Loading ...
Support Center